LLY vs REGN
By Alex · Tickerpine
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | REGN |
|---|---|---|
| Price | $1,220.28 | $797.99 |
| Market cap | $1.09T | $82.16B |
| P/E ratio | 41.0 | 19.7 |
| ROE | 102.29% | 14.04% |
| Profit margin | 33.53% | 27.87% |
| Revenue growth | 47.70% | 16.70% |
| Dividend yield | 0.57% | 0.47% |
| Beta | 0.51 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs REGN in plain English
- LLY is the bigger company — about 13.2× the market cap of REGN.
- REGN is cheaper on earnings (P/E 19.7 vs 41.0).
- LLY earns a higher return on equity (102% vs 14%).
- LLY is growing revenue faster (48% vs 17%).
- LLY has the higher dividend yield (0.57% vs 0.47%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.